JelloX Debut Highlights Potential to Disrupt Cancer Pathology

SAN FRANCISCO, Nov. 8, 2022 /PRNewswire/ -- JelloX Biotech's debut at Intel® Innovation in September drew the attention of healthcare experts and pharmaceutical brands alike for the Taiwan-based startup's potential to shape the future of cancer pathology using 3D imaging technology....

Click to view original post